Key Takeaways:

• The acquisition brings together two highly complementary, science-backed skincare brands.
• The transaction expands Galderma’s Dermatological Skincare portfolio in the growing physician-dispensed skincare segment.
• Galderma’s unique Integrated Dermatology Strategy, global scale, and omnichannel execution capabilities will support  ZO Skin Health’s next phase of growth.

BeautyMatter 2024 FUTURE50 brand ZO Skin Health makes strategic exit.

WHO: Founded by dermatologist Dr. Zein Obagi and headquartered in Irvine, California, ZO Skin Health has been a reference name in clinically backed professional skincare for more than two decades. Its broad product portfolio, spanning over 40 products, is manufactured in the US and sold through a network of more than 16,500 physician, medical spa, and online accounts across more than 40 countries, supported by a dedicated salesforce and medical education team.

Galderma is the pure-play dermatology category leader, present in approximately 90 countries. Galderma delivers an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Since its foundation in 1981, Galderma has dedicated its focus and passion to the human body's largest organ—the skin—meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals.

Blackstone is the world’s largest alternative asset manager. Blackstone seeks to deliver compelling returns for institutional and individual investors by strengthening the companies in which the...